Log In
Print this Print this

Relenza, zanamivir

Also known as: GG167

  Manage Alerts
Collapse Summary General Information
Company Aviragen Therapeutics Inc.
DescriptionInhaled influenza neuraminidase inhibitor
Molecular Target Neuraminidase
Mechanism of ActionNeuraminidase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationInfluenza virus
Indication DetailsPrevent influenza A and B infections; Treat and prevent H1N1 influenza in pregnant and breastfeeding women; Treat and prevent influenza; Treat and prevent swine influenza A (H1N1); Treat influenza only in "at risk" adult and children
Regulatory Designation
PartnerGlaxoSmithKline plc;
Medivir AB

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today